Operations at Seattle-based ZymoGenetics, which is owned by Bristol-Myers Squibb, has been winding down for the last few years. Now the complete end is within months.
Last week, BMS announced that it will shutter the plant and layoff its 63 employees, starting next month.
BMS bought ZymoGenetics, Seattle’s oldest biotech company, in 2010 for $885 million. In 2015, the company moved 40 employees out of Seattle into other facilities around the U.S., and in 2016, announced it would not renew the lease on ZymoGenetic’s historical manufacturing space. A cancer research center plans to take over the space starting next year.
BMS stated that the move is part of a larger effort in the company to restructure its R&D operations.
ZymoGenetic makes therapeutic proteins for cancer treatments, and has another facility that employs about 70 people that will stay open.